Genetron Health to Announce Second Quarter Unaudited Financial Results and Host Investor Call on August 6, 2020
July 27 2020 - 4:30PM
Genetron Holdings Limited (“Genetron Health” or the “Company”,
NASDAQ:GTH), a leading precision oncology company in China that
specializes in offering molecular profiling tests, today announced
that it will report unaudited financial results for the second
quarter ended June 30, 2020, on August 6, 2020, before the US
market open.
Management will host a conference call for
investors at 8:30 a.m. ET (8:30 p.m. Beijing time) on Thursday,
August 6, 2020. The conference call can be accessed by dialing the
following numbers:
United States: |
+1 845-675-0437 |
China Domestic: |
400-620-8038 |
Hong Kong: |
+852-3018-6771 |
International: |
+65-6713-5090 |
Conference ID: |
1969177 |
Participants are encouraged to dial into the
call at least 15 minutes in advance due to high call volumes.
A replay will be accessible through September 6,
2020, by dialing the following numbers:
United States: |
+1-646-254-3697 |
International: |
+61-2-8199-0299 |
Conference ID: |
1969177 |
A simultaneous webcast of the conference call
will be available on the "News and Events" page of the Investors
section of the Company's website. A replay of the webcast will be
available for 30 days following the event. For more information,
please visit ir.genetronhealth.com.
About Genetron Holdings
Limited
Genetron Holdings Limited (“Genetron Health” or
the “Company”) is a leading precision oncology platform company in
China that specializes in cancer molecular profiling and harnesses
advanced technologies in molecular biology and data science to
transform cancer treatment. The Company has developed a
comprehensive oncology portfolio that covers the entire spectrum of
cancer management, addressing needs and challenges from early
screening, diagnosis and treatment recommendations, as well as
continuous disease monitoring and care. Genetron also partners with
global biopharmaceutical companies and offers customized services
and products. For more information, please visit
ir.genetronhealth.com.
Safe Harbor Statement
This press release contains forward-looking
statements. These statements are made under the “safe harbor”
provisions of the U.S. Private Securities Litigation Reform Act of
1995. Statements that are not historical facts, including
statements about the Company’s beliefs and expectations, are
forward-looking statements. Forward-looking statements involve
inherent risks and uncertainties, and a number of factors could
cause actual results to differ materially from those contained in
any forward-looking statement. In some cases, forward-looking
statements can be identified by words or phrases such as “may”,
“will,” “expect,” “anticipate,” “target,” “aim,” “estimate,”
“intend,” “plan,” “believe,” “potential,” “continue,” “is/are
likely to” or other similar expressions. Further information
regarding these and other risks, uncertainties or factors is
included in the Company’s filings with the SEC. All information
provided in this press release is as of the date of this press
release, and the Company does not undertake any duty to update such
information, except as required under applicable law.
Investor Relations
ContactsUS:Hoki LukHead of Investor RelationsEmail:
hoki.luk@genetronhealth.comPhone: +1 (408) 204-5343
Stephanie CarringtonWestwicke, an ICR CompanyEmail:
Stephanie.Carrington@westwicke.comPhone: +1 (646) 277-1282
Asia:Bill ZimaICR, Inc.Email:
bill.zima@icrinc.comGenetronIR@icrinc.com
Media Relations ContactEdmond
LococoICREdmond.Lococo@icrinc.comMobile: +86
138-1079-1408genetron.pr@icrinc.com
Genetron (NASDAQ:GTH)
Historical Stock Chart
From Sep 2024 to Oct 2024
Genetron (NASDAQ:GTH)
Historical Stock Chart
From Oct 2023 to Oct 2024